Smart Dividend Portfolio: Cash Cure
1
Dear Investor,
Welcome to our weekly edition of TipRanks’ Smart Dividend Portfolio & Newsletter.
1
1
Market-Moving News: May 18, 2026
Last week, stocks pulled back from record highs as oil, yields, and interest rates returned to the forefront. The S&P 500 (SPX) ended at 7,408.50, down 1.24% on Friday, while the Nasdaq 100 (NDX) fell 1.54% to 29,125.20. The Dow Jones (DJIA) slipped 1.07% to 49,526.17 after briefly moving back above the 50,000 mark earlier in the week.
At the same time, the S&P 500 still managed to post its seventh straight weekly gain. That kept the broader uptrend alive, even as the Nasdaq 100 and Russell 2000 (IWM) ended the week lower. The main pressure came from higher oil prices, rising bond yields, and fresh fear that the Federal Reserve may need to stay tough if inflation heats up again.
The U.S. 10-year yield rose to 4.597%, while oil (CM:CL) jumped 4.44% to $105.31. Gold (CM:XAUUSD) fell 3.02% to $4,540.50, while Bitcoin (BTC-USD) traded near $78,132, down 0.17%, as it gave back part of its upward move after the CLARITY Act cleared the Senate Banking panel.
The key macro point was the Strait of Hormuz. Stocks weakened as investors grew more alert to the risk that a supply shock could push fuel costs higher. That would make the Fed’s job much harder. Traders are now pricing in a 38% chance of a rate hike before 2027, up from 20% one week ago.
Looking ahead, oil may be the most important macro swing factor. If risks near the Strait of Hormuz grow, crude could stay high and feed fresh inflation fears. That would keep pressure on bond yields and may force investors to rethink the path for Fed policy.
At the same time, AI will remain the market’s core theme. Nvidia, Cisco, Microsoft, and the broader chip group will need to keep proving that AI demand is still strong enough to support high stock prices. Cerebras may also stay in focus as investors test how much room there is for new AI chip names outside Nvidia.
In addition, investors will watch whether the rally can broaden. The S&P 500 has now logged seven straight weekly gains, but the weakness in small caps and the Nasdaq 100 shows that confidence is not spread across the whole market. If more sectors join in, the rally may look healthier. If not, the market may depend too much on a small group of large tech names.
Finally, the Fed will remain a key risk. Sticky prices, higher oil, and a 10-year yield near 4.6% could keep rate cut hopes in check.
1
1
This Week’s Quality Dividend Stock Idea
Abbott Laboratories (ABT) is a U.S.-based healthcare company that develops, manufactures, and markets products across medical devices, diagnostics, nutrition, and branded generic medicines. Its portfolio includes diabetes care, cardiovascular devices, rapid diagnostic testing, infant nutrition, and adult health products, serving hospitals, laboratories, physicians, and consumers worldwide.
1
Pulse Shift
Abbott Laboratories traces its origins to 1888, when physician Wallace C. Abbott founded the company in Chicago to manufacture standardized pharmaceutical formulations derived from active alkaloids. Over the following decades, Abbott expanded internationally and diversified beyond traditional medicines, building a broad healthcare platform spanning pharmaceuticals, diagnostics, nutrition, and medical devices. This diversification became a defining driver of the company’s long-term earnings resilience.
A major turning point came in the second half of the 20th century as Abbott increased investment in research, diagnostics, and global expansion. The company established strong positions in branded pharmaceuticals and hospital products while steadily expanding its international footprint, particularly in emerging markets. During the 1980s and 1990s, Abbott strengthened its diagnostics business through automation and laboratory testing systems, creating recurring revenue streams tied to consumables, testing platforms, and installed equipment bases.
In the 2000s, Abbott accelerated growth through acquisitions and portfolio reshaping. The 2001 acquisition of Knoll’s pharmaceutical business added the blockbuster rheumatoid arthritis drug Humira, which became one of the world’s highest-selling medicines and significantly boosted Abbott’s earnings and cash flow for more than a decade. Abbott also expanded its vascular and diabetes device franchises through acquisitions such as Guidant’s vascular business in 2006 and Advanced Medical Optics in 2009, broadening its exposure to faster-growing medical technology markets.
A transformational restructuring occurred in 2013 when Abbott separated its research-based pharmaceutical business into AbbVie. AbbVie retained Humira, while Abbott repositioned itself as a diversified medical products company focused on diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. The spin-off reduced Abbott’s dependence on patent-driven pharmaceutical revenue and marked a strategic shift toward recurring, technology-driven healthcare markets.
Following the separation, Abbott accelerated its expansion through a series of major acquisitions and divestitures designed to strengthen higher-growth businesses. In 2015, the company sold its developed markets branded generics business to Viatris as part of its broader portfolio refocusing strategy. Abbott also divested Abbott Medical Optics to Johnson & Johnson and later sold its animal health business to Zoetis to concentrate resources on human healthcare and medical technology.
Growth accelerated further in 2017 with the acquisitions of St. Jude Medical and Alere. The acquisition of St. Jude Medical transformed Abbott into a cardiovascular device powerhouse by expanding its presence in atrial fibrillation, heart failure, structural heart, and electrophysiology therapies. Later that year, Abbott acquired Alere after a lengthy renegotiation process, establishing the company as a global leader in point-of-care diagnostics.
At the same time, Abbott benefited from the rapid adoption of its FreeStyle Libre continuous glucose monitoring (CGM) platform, which became one of the company’s most important long-term growth engines in diabetes care. Abbott continued expanding its medical technology portfolio through targeted acquisitions, including Cardiovascular Systems in 2023 to strengthen its vascular intervention portfolio and Bigfoot Biomedical to expand its digital diabetes management capabilities.
1
Diagnostic Frontier
More recently, Abbott expanded aggressively into oncology diagnostics through an approximately $21 billion acquisition of Exact Sciences earlier this year. The transaction added products such as Cologuard and Oncotype DX and established Abbott’s first large-scale presence in cancer diagnostics, creating another high-growth platform within its diagnostics segment.
The acquisition of Exact Sciences, which was completed in March, was the most significant strategic development highlighted during Abbott’s first-quarter 2026 earnings call. Management described it as more than a typical acquisition, calling it Abbott’s formal entry into the rapidly growing cancer diagnostics market. Abbott also established a dedicated Cancer Diagnostics business and restated prior-year diagnostics results to include the new category, signaling that oncology testing is expected to become a permanent and increasingly important growth driver.
At the center of the acquisition is Cologuard, Exact Sciences’ non-invasive colorectal cancer screening test. Comparable sales rose 13% year-over-year in the first quarter, while international markets grew in the high teens. The company noted that nearly 50 million Americans remain behind on recommended colorectal cancer screenings, leaving substantial untapped demand. Abbott also sees long-term opportunity because U.S. colonoscopy capacity has remained relatively flat at about 6 million procedures annually, creating room for at-home screening alternatives.
Recurring demand further strengthens the business model, as patients typically repeat Cologuard screenings every three years. Rescreening already accounts for about 25% of total test volumes, creating a growing and potentially more predictable revenue stream as adoption increases. Abbott also views Exact Sciences as more than a single-product acquisition, seeing opportunities in broader oncology diagnostics markets such as therapy selection and minimal residual disease (MRD) testing, which supports earlier detection, precision medicine, and ongoing patient monitoring. The company is also pursuing international expansion through its global distribution network. Management said integration efforts are progressing “extremely well,” and appointed Jake Orville to lead the new Cancer Diagnostics business, which reports directly to CEO Robert Ford, underscoring its strategic importance as a future growth engine.
Today, Abbott’s earnings profile reflects decades of diversification, acquisitions, and portfolio optimization that transformed the company into a global leader in diagnostics, medical devices, nutrition, and branded generics, supported by recurring revenue, strong cash generation, and broad international scale.
1
Vital Streams
Abbott Laboratories operates a diversified healthcare business model spanning medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals. The company generates revenue primarily through the sale of healthcare products to hospitals, laboratories, healthcare systems, pharmacies, retailers, and government agencies across more than 160 countries. Its broad portfolio reduces dependence on any single product category while providing exposure to multiple long-term healthcare growth markets.
Abbott’s largest earnings driver is its Medical Devices segment, which accounts for roughly 49% of total sales and includes cardiovascular devices, electrophysiology products, heart failure therapies, neuromodulation systems, and diabetes care products. The company’s FreeStyle Libre CGM platform has become a major growth engine, benefiting from rising global diabetes prevalence and increasing adoption of wearable glucose monitoring technology. Abbott also generates recurring revenue from consumables, replacement sensors, catheters, and procedure-based products tied to its installed medical device base, supporting high customer retention and recurring cash flow generation.
The Diagnostics segment provides another important source of recurring revenue, contributing approximately 10% of total revenue in the first quarter. Abbott sells laboratory diagnostic systems, rapid testing products, and molecular diagnostics platforms used by hospitals and healthcare providers worldwide. Once diagnostic platforms are installed, customers typically purchase testing consumables and reagents on an ongoing basis, creating strong revenue model with predictable demand and high switching costs. The 2026 acquisition of Exact Sciences further expanded Abbott’s presence into high-growth cancer diagnostics markets, including colorectal cancer screening and genomic testing.
Abbott also maintains sizable Nutrition and Established Pharmaceuticals businesses, with the two segments together accounting for around 30% of the company’s total revenue. Its nutrition segment includes globally recognized pediatric and adult nutrition brands, while its branded generics business focuses primarily on emerging markets, where rising healthcare access and growing middle-class populations continue to support demand growth.
A key strength of Abbott’s business model is its balance between innovation-driven growth and recurring revenue stability. Many of its products operate in essential healthcare categories with durable demand, while diversification across geographies and product segments reduces earnings volatility. The company also benefits from significant scale, global distribution infrastructure, and strong operating margins, which support consistent free cash flow generation and ongoing investment in research, product development, and acquisitions aimed at expanding future growth opportunities.
1
Rhythm Engine
Abbott Laboratories delivered broad-based growth across most of its major business segments during the first quarter of 2026, reinforcing management’s view that the company’s long-term growth drivers remain intact despite temporary headwinds in diagnostics and nutrition.
Medical Devices remained Abbott’s strongest business, with comparable sales growth of approximately 8.5%. Electrophysiology was a major contributor, growing 13% due to early launches of Abbott’s new pulsed field ablation (PFA) catheters – Volt in the United States and TactiFlex Duo in Europe. PFA technology is viewed as one of the most important innovations in atrial fibrillation treatment because it may improve procedural efficiency while reducing damage to surrounding tissue. Management highlighted Volt’s potential ability to support procedures under conscious sedation rather than full anesthesia, which could simplify workflows and improve hospital capacity utilization. Early clinical data also suggests the technology may create more durable lesions, potentially improving long-term patient outcomes and strengthening physician adoption. Abbott expects electrophysiology growth to accelerate as commercialization expands later this year.
Other cardiovascular businesses also remained strong. Rhythm Management, that is, heart rhythm control devices, grew 13% for the third consecutive quarter of double-digit growth, while Heart Failure (devices for weakened hearts) increased 12% due to continued demand for Abbott’s ventricular assist devices. Within Structural Heart (devices that repair heart structures), management acknowledged competitive pressure in the U.S. mitral valve market, but international structural heart therapies, including mitral and TriClip products, continued delivering double-digit growth. Abbott still expects high-single-digit growth for the segment this year.
Diabetes Care generated roughly $2 billion in quarterly revenue and grew 7.5%, below management’s original expectations. One factor affecting growth was a delay in renewing a major international reimbursement tender. In many government-funded healthcare markets, reimbursement agreements determine patient access and product purchases, so delays can temporarily slow shipments as healthcare providers and distributors wait for updated approvals. Management indicated that this was a timing-related administrative issue rather than a sign of weakening demand for Abbott’s diabetes products. The second headwind came from difficult year-over-year comparisons due to elevated distributor restocking activity in early 2025. Higher inventory purchases during the prior-year period temporarily boosted reported Diabetes Care revenue, creating a tougher comparison base and making current growth appear weaker despite healthy underlying demand.
Despite the temporary slowdown, management expects growth to return to double digits beginning in the second quarter. The company remains highly bullish on the long-term continuous glucose monitoring (CGM) market, estimating that 70 million to 80 million people globally could eventually use CGMs compared with only 10 million to 12 million users today. Abbott estimates the addressable market at approximately $30 billion to $35 billion annually.
Management also highlighted several upcoming catalysts that could further expand the CGM market, including potential U.S. insurance coverage expansion for Type 2 diabetes patients not using insulin, which could add roughly 10 million eligible patients. International reimbursement expansion across several major markets also remains ongoing. In addition, Abbott expects potential second-half 2026 approval for an upgraded diabetes monitoring sensor that can measure both blood sugar (glucose) and ketone levels at the same time. This is important because ketones can rise to dangerous levels when the body lacks enough insulin, making the device potentially more useful for people using insulin pumps and patients taking certain diabetes drugs known as SGLT2 therapies, which can increase the risk of ketone-related complications.
1
Diagnostic Rebound
Within the Diagnostics business segment, comparable sales increased roughly 2%. Core Laboratory Diagnostics grew 3%, supported by demand in the United States, Europe, and Latin America. Importantly, China sales stabilized after severe pressure throughout 2024 from the country’s Volume-Based Procurement (VBP) program,1 which had caused quarterly declines of 15% to 30%. Management said approximately 80% of Abbott’s China diagnostics portfolio has now moved through the VBP process, reducing a major overhang on the business.
Abbott also maintained U.S. contract renewal rates above 90% and new business win rates above 55%, supporting confidence in the competitiveness of its diagnostic platforms. Management expects Core Lab growth to accelerate during the second half of 2026 and finish the year at a mid-single-digit growth rate.
Rapid and Molecular Diagnostics declined 10% because the respiratory virus season was significantly weaker than the unusually strong 2025 season. However, management deliberately excluded any potential rebound in fourth-quarter respiratory testing demand from guidance, reflecting a conservative forecasting approach. The company noted that it already has the manufacturing and distribution capacity to capture upside if respiratory testing demand strengthens later this year.
The Established Pharmaceuticals Division (EPD), which primarily sells branded generic medicines in emerging markets, grew 9%, including double-digit growth across several Latin American and Asia Pacific countries. Management attributed the performance to rising healthcare access, favorable demographic trends, increasing healthcare spending, and expansion of Abbott’s biosimilars portfolio, including oncology-related therapies.
Abbott also used the quarter to reinforce its broader 2026 growth framework, which management divides into three major drivers. The first is continued strong growth from Medical Devices and EPD. The second is recovery in businesses that faced temporary pressure, particularly Core Lab Diagnostics in China and Nutrition. The third is the addition of Exact Sciences, which provides Abbott with exposure to the fast-growing cancer diagnostics market.
Management also addressed broader macroeconomic and geopolitical concerns. Despite recent oil price volatility and Middle East shipping disruptions, Abbott said it has not seen meaningful increases in freight costs, supplier expenses, or demand weakness. The primary impact in the Middle East was logistical rather than demand-related, leading Abbott to build additional regional inventory buffers to protect supply continuity. Importantly, management reported no signs of reimbursement pressure or reduced healthcare demand in affected markets, underscoring the resilience of Abbott’s globally diversified healthcare portfolio.
—
1- China’s VBP program is a government initiative that lowers healthcare costs by purchasing large volumes of medical products at negotiated prices.
1
Medical Flywheel
Over the past five years, Abbott’s financial performance has reflected a transition from pandemic-driven growth toward a more diversified set of long-term healthcare growth engines. Revenue and EPS grew at a CAGR of 4% and 3.1%, respectively, as Abbott shifted its growth profile toward businesses with stronger recurring demand characteristics, including its FreeStyle Libre diabetes platform, electrophysiology products, and branded generics operations in emerging markets. More recently, the company added another potential growth driver through its acquisition of Exact Sciences and expansion into oncology diagnostics.
The company’s earnings growth has also been shaped by several opposing forces over this period. EPS benefited from operating leverage within the higher-margin Medical Devices business, ongoing share repurchases, and recurring revenue generated by installed device and diagnostics platforms. At the same time, earnings faced pressure from the decline in high-margin COVID testing revenue, litigation-related costs, weakness within the Nutrition segment, pricing pressure in China, and near-term dilution associated with the Exact Sciences acquisition.
Abbott’s first-quarter 2026 results illustrated this balancing dynamic. The company reported adjusted EPS of $1.15, representing 6% year-over-year growth and meeting management’s guidance despite multiple temporary headwinds. Results were affected by early financing costs tied to the Exact Sciences acquisition and a weaker-than-expected respiratory testing season, which pressured portions of the Diagnostics business.
Despite those challenges, overall business performance remained solid. Total revenue reached $11.2 billion, increasing 7.8% year-over-year and modestly exceeding expectations. Comparable sales rose 3.7%, driven primarily by continued strength in Medical Devices and Core Diagnostics. Revenue growth also benefited from favorable foreign exchange movements, as a weaker U.S. dollar during the quarter created an approximately 4% tailwind.
Profitability remained relatively resilient despite integration costs and broader operating pressures. Adjusted gross margin was 56.3%, reflecting the contribution of Abbott’s higher-margin medical device and diagnostics businesses. The company continued investing in future growth initiatives, with research and development expenses accounting for 6.7% of sales, while selling, general, and administrative expenses represented 29.3% of revenue as Abbott supported global commercialization activities and Exact Sciences integration efforts.
From a financial quality perspective, Abbott continues to maintain strong profitability metrics, with ROE and ROA ranking among the top 20% of the industry and ROIC within the top 25%. The company’s debt-to-EBITDA ratio of 2.8x remains elevated primarily because of its acquisition-driven strategy rather than operational weakness. The Exact Sciences transaction contributed significantly to leverage, including approximately $2.8 billion of acquired debt, of which $1.4 billion had already been repaid in March 2026, with the remainder expected to be repaid during the year.
Despite higher leverage, Abbott continues to maintain strong investment-grade credit ratings of “A+” from S&P Global Ratings and “Aa3” from Moody’s Investors Service, reflecting confidence in the company’s financial stability and long-term cash generation profile.
Management expects earnings growth to strengthen through the remainder of the year. For the second quarter of 2026, Abbott guided for adjusted EPS of approximately $1.28 at the midpoint, implying sequential acceleration as acquisition-related costs moderate and key device and diagnostics franchises continue expanding. For FY26, the company reiterated expectations for comparable sales growth of 6.5% to 7.5% and projected adjusted EPS of approximately $5.48 at the midpoint.
Importantly, this outlook already includes approximately $0.20 of earnings dilution related to the Exact Sciences acquisition, suggesting that management still expects meaningful underlying growth from its core businesses while integrating a major transaction and building its presence in oncology diagnostics.
1
Dividend Dose
Abbott has maintained one of the longest dividend records in the healthcare sector, paying dividends continuously since 1924 and increasing its payout for 51 consecutive years, earning its status as a Dividend Aristocrat. Based on adjusted earnings, the company distributes approximately 47% of profits to shareholders. Abbott’s dividend yield currently stands at 1.88%, modestly above the healthcare sector average of 1.66%. For the most recent quarter, the company declared a dividend of $0.63 per share, representing a 6.8% year-over-year increase and reinforcing management’s commitment to steady shareholder returns.
Abbott has also continued returning capital through share repurchases. In October 2024, the company authorized a program allowing the repurchase of up to $7 billion of common shares over time. As of March 31, 2026, approximately $6.7 billion remained available under the authorization, providing additional flexibility to support shareholder value creation.
Despite these strengths, Abbott’s shares have declined by more than 36% over the past year as investors weighed several major concerns. These included rising litigation risks tied to NEC infant formula cases involving Similac products,2 the normalization of COVID-era diagnostics revenue, weakness within the Nutrition business, and short-term earnings dilution associated with the Exact Sciences acquisition.
The decline has materially reduced Abbott’s valuation relative to both its own history and peers. The stock currently trades at more than a 30% discount to its historical averages based on non-GAAP trailing and forward P/E multiples and forward EV/EBITDA, while trading at more than a 20% discount based on forward price-to-cash-flow metrics. Relative to peers such as Johnson & Johnson, DexCom, Medtronic, Boston Scientific, and Edwards Lifesciences, Abbott currently trades within the low-to-moderate valuation range across non-GAAP trailing and forward P/E ratios, forward EV/EBITDA, and price/ cash flows. This suggests investors are paying a mid-range valuation for a company with stable cash generation and multiple future growth opportunities rather than assigning a premium growth multiple.
Analysts remain bullish about ABT as the company’s diversified healthcare portfolio across Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals reduces dependence on any single market, supporting more stable revenue growth and long-term earnings resilience. The company also maintains a strong balance sheet and conservative leverage profile, providing flexibility to fund acquisitions, R&D, and shareholder returns.
The Exact Sciences acquisition further strengthens this long-term growth profile by expanding Abbott’s presence in cancer diagnostics and precision medicine, creating another recurring revenue opportunity in a large and growing market. Reflecting these factors, Street consensus implies approximately 42% upside from current share levels, while more optimistic estimates suggest potential gains of up to 69%. Discounted cash flow analysis also indicates that Abbott shares may be trading at roughly a 38% discount to estimated intrinsic value, providing additional valuation support for long-term investors.
—
2- Abbott is managing ongoing litigation related to claims involving its Similac infant formulas contributed to necrotizing enterocolitis (NEC) in premature infants, with the company actively appealing recent jury verdicts. While the cases remain a near-term financial and reputational overhang, they are currently viewed as a risk factor to monitor rather than a direct threat to Abbott’s diversified business model.
Investing Takeaway
For income-focused investors, Abbott stands out less as a high-yield stock and more as a long-term dividend compounder supported by durable healthcare demand. The company’s diversified business structure, recurring revenue streams from devices and diagnostics, and strong cash generation have allowed it to maintain a long record of consistent dividend growth across multiple economic cycles and industry disruptions. While near-term challenges such as litigation exposure, Nutrition weakness, and acquisition-related dilution have weighed on sentiment, the underlying business continues generating stable cash flows that support both dividend payments and share repurchases. The expansion into cancer diagnostics through Exact Sciences, combined with growth opportunities in diabetes care and medical devices, also creates additional avenues for future cash flow generation. For investors prioritizing steadily growing income rather than maximizing current yield, Abbott offers a combination of stability, resilience, and long-term dividend growth potential.
1
1
Dividend Investor Portfolio
1
Portfolio News
▣ BlackRock (BLK) is reportedly exploring a potential multibillion-dollar investment in the planned initial public offering of SpaceX through its actively managed funds. Although discussions remain in the early stages and no formal transaction has been announced, the move would align with BlackRock’s broader strategy of expanding access to high-profile private-market opportunities before they enter public markets. As demand for private assets continues to rise, large institutional investors increasingly view early exposure to industry leaders as a way to enhance long-term returns and diversify investment offerings.
▣ Cisco (CSCO) delivered a strong third-quarter fiscal 2026 performance as accelerating AI demand and a broad recovery in networking continued to reshape the company’s growth profile. The company reported record quarterly revenue of $15.8 billion, up 12% year-over-year, while adjusted EPS rose 10% to $1.06, exceeding the high end of management’s guidance. Networking remained a major driver, with networking product revenue increasing 25% and product orders rising 35% overall. Cisco also reported more than 50% growth in networking orders and over 40% growth in data center switching orders, reflecting strong enterprise and hyperscaler demand. AI momentum accelerated significantly, with AI infrastructure orders reaching $5.3 billion year-to-date, prompting management to raise its FY26 expectation to $9 billion from a prior target of $5 billion. Reflecting this strength, Cisco increased full-year FY26 revenue guidance to $62.8-$63.0 billion and raised adjusted EPS guidance to $4.27-$4.29.
▣ ExxonMobil (XOM) secured a favorable outcome in a long-running shareholder lawsuit after a Texas jury found the company was not liable in claims tied to accounting treatment for its Canadian oil sands and Rocky Mountain gas assets. The case had dated back to 2016 and involved allegations that the company misled investors regarding asset valuations and potential climate-related impacts. The ruling removes a legal overhang that had persisted for nearly a decade and reduces uncertainty surrounding a closely watched case.
Separately, Exxon resumed exploration activity in Guyana’s Canje block after an absence of more than four years. The company operates the block with a 35% stake alongside partners, and is returning despite earlier exploration efforts of three wells that had mixed or non-commercial results. The Canje block lies adjacent to Guyana’s highly successful Stabroek block, where Exxon and its partners have discovered more than 11 billion barrels of recoverable oil resources. While Canje remains a higher-risk exploration area, renewed drilling reflects Exxon’s continued willingness to pursue potentially large offshore opportunities that could support future reserve additions and long-term production growth.
1
Recent Trades
None at the moment, although we are considering adding a stock to our portfolio when the market conditions allow for an attractive entry point. Stay tuned.
1
1
Portfolio Attributes
| Dividend Portfolio Yield |
Expected Dividend Growth | Expected Annual Income |
| 3.94% | +5.97% | $6,164.34 |
| Yield-on-Cost Adjusted, Weighted |
Average Analyst 12-Month Growth Outlook | 10K Per Stock at the Time of Purchase |
1
Current Portfolio
| Name | EX-Dividend Date | Payment Date | Yield on Cost | Annual DPS |
| Automatic Data Processing (ADP) | Jun 15, 2026 | Jul 01, 2026 | 2.46% | $6.80 |
| Amgen (AMGN) | May 15, 2026 | Jun 05, 2026 | 3.27% | $10.08 |
| BlackRock (BLK) | Jun 05, 2026 | Jun 23, 2026 | 2.61% | $22.92 |
| Bank of Nova Scotia (BNS) | Jul 02, 2026 | Jul 29, 2026 | 5.98% | $3.21 |
| EOG Resources (EOG) | Jul 16, 2026 | Jul 30, 2026 | 3.06% | $4.08 |
| ExxonMobil (XOM) | May 15, 2026 | Jun 10, 2026 | 3.64% | $4.12 |
| Honeywell International (HON) | May 15, 2026 | Jun 05, 2026 | 2.39% | $4.76 |
| IBM (IBM) | Aug 06, 2026 | Sep 10, 2026 | 3.16% | $6.76 |
| JPMorgan Chase (JPM) | Jul 03, 2026 | Jul 31, 2026 | 3.43% | $6.00 |
| Kroger (KR) | May 15, 2026 | Jun 01, 2026 | 3.08% | $1.40 |
| Cisco Systems (CSCO) | Jul 02, 2026 | Jul 23, 2026 | 2.22% | $1.68 |
| PepsiCo (PEP) | Jun 05, 2026 | Jun 30, 2026 | 3.8% | $5.69 |
| Philip Morris (PM) | Jun 29, 2026 | Jul 15, 2026 | 6.06% | $5.88 |
| Qualcomm (QCOM) | Jun 05, 2026 | Jun 26, 2026 | 2.44% | $3.68 |
| VICI Properties (VICI) | Jun 18, 2026 | Jul 10, 2026 | 5.22% | $1.8 |
| Verizon (VZ) | Jul 09, 2026 | Aug 03, 2026 | 6.09% | $2.76 |
1
1
Click here for additional Newsletters from TipRanks’ Macro & Markets Research Analysis Team
1
Disclaimer
The information contained in this article represents the views and opinions of the writer only, and not the views or opinions of TipRanks or its affiliates and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy, or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment, and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices, or performance.
